top of page

Your content has been submitted

Your content has been submitted

Your content has been submitted

An error occurred. Try again later

Your content has been submitted

An error occurred. Try again later

Your content has been submitted

An error occurred. Try again later

An error occurred. Try again later

An error occurred. Try again later

Your content has been submitted

Your content has been submitted

Your content has been submitted

Your content has been submitted

Your content has been submitted

Your content has been submitted

Your content has been submitted

Your content has been submitted

An error occurred. Try again later

An error occurred. Try again later

Your content has been submitted

Your content has been submitted

Your content has been submitted

Elevating lives with NanoTech Cannabinoid Medicine

We are a clinical-stage life sciences company focused on the research and clinical development of cutting-edge nano drug delivery technology & medicines for symptomatic relief of neurological diseases.

30

Countries

including the US FDA, have already approved cannabinoid-based drugs for treatment of MS-related Spasticity & rare forms of epilepsy

$800

Million

of revenue generated in 2022 for approved cannabinoid-based medicines

but existing approved cannabinoid medicines are sub-optimal due to poor oral absorption.

Elixie has developed a high-absorption drug-delivery technology called NANOLIX, which has been clinically proven to promote the fast, efficient and consistent absorption of cannabinoids and maximize efficacy.

Instant Relief

Quicker onset of action : 4x faster

Bioavailability

Higher rate of efficacy
at a small dose

Consistent Absorption

Predictable and repetitive effect relief for spasticity sufferers

Self Nano Emulsifying Drug Delivery System (SNEDDS) for Oral Drugs

NANOLIX encapsulates cannabinoids in nanoemulsions and is used as a platform to enhance and expand existing API’s, creating cannabinoid 'super drugs' for rapid relief.

NANOLIX Patented

Technology

EU - Granted

US | Canada | Pending

01

NANOLIX pre-concentrated composition of cannabinoids and Pro-Nano liposphere formulation.

02

In contact with water, NANOLIX spheres spontaneously formed around the cannabinoids.

03

The cannabinoids are encapsulated in NANOLIX nanoparticles.

Clinically validated and published in 6 peer reviewed publications

Learn More

Key International Research and Clinical Collaborators

Elixie Products

We enhance clinically proven API’s with our Nanolix Technology to create highly soluble and affective cannabinoid-based medicines. We have two medicines in development, Elidiol,targets rare forms of Epilepsy. Our second product Elinol, targets a “rare” neurodegenerative disease. Both Elidiol and Elinol are eligible for FDA orphan disease designation.

————— Elidiol®
—————Elinol®

Elidiol

NANOLIX & Cannabidiol (Purified CBD)

Elidiol Oral emulsion is created by combining NANOLIX with Cannabidiol (Purified CBD) to accelerate drug absorption and provide rapid symptomatic relief for rare epilepsy.





The successful in-human pharmacokinetic and safety studies formed the foundation for advancing to Phase 1 clinical trials and seeking FDA marketing approval.

Elinol

NANOLIX & Cannabinoids (THC + CBD)

Elinol Oral emulsion is created through a combination of NANOLIX with Tetrahydrocannabinol (THC) and Cannabidiol (CBD) to accelerate drug absorption and provide rapid relief from spasticity for patients suffering from neurodegenerative diseases such as multiple sclerosis (MS).

 


The successful in-human pharmacokinetic and safety studies formed the foundation for advancing to Phase 1 clinical trials and seeking FDA marketing approval.

Product Development Pipeline

Drug Candidate

Pre-Clinical

Phase 0

Phase 1

Phase 2/3

Marketing

Approval

Elidiol®

NANOLIX® + Cannabidiol

(Purified CBD)

Elinol is eligible for FDA orphan disease designation.

Anticonvulsant medication

Elinol is eligible for FDA orphan disease designation.

Elinol®

NANOLIX® + Cannabinoids

(THC + CBD)

Elinol is eligible for FDA orphan disease designation.

Spasticity relief drug

Elinol is eligible for FDA orphan disease designation.

Elixie was founded in 2019 with its headquarters located in Tel Aviv, Israel. Our deep commitment lies in addressing the pressing healthcare challenges faced by millions of individuals living with chronic conditions.

Elixie is powered by a dedicated team of passionate visionaries who bring together diverse expertise and unwavering commitment. We share a common belief in the transformative power of science, and our relentless pursuit of excellence propels us to explore uncharted territories in nanotechnology, pushing the boundaries to provide innovative solutions for relief.

Join us in driving nano-tech healthcare innovation

forward

Headquarters

No. 4 Ariel Sharon St., Givatayim, Israel

R&D lab:

Tarshish Industrial Park St 5, Caesarea, Israel

Created by Zenverse Studio

Your content has been submitted

2023 Elixie. All right reserved.

bottom of page